Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis

24 Jul 2022

Abstract excerpt

INTRODUCTION: The presence of high-risk chromosomal abnormalities [t(4;14), del(17p), and t(14;16)] has been linked with inferior outcomes in patients with multiple myeloma (MM). A prespecified interim analysis of the Phase 3 IKEMA study (NCT03275285) demonstrated that isatuximab (Isa) + carfilzomib (K) and dexamethasone (d; Isa-Kd) significantly improved progression-free survival (PFS) versus Kd in patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosomal and Genetic Variations
Share to Immunotherapy and Immune Responses
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35871357
DOI: 10.1111/ejh.13835

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysisPMID 35871357Read ↗

Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogeneticsSemantic proximity Read ↗

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myelomaSemantic proximity Read ↗

Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment responseSemantic proximity Read ↗

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial resultsSemantic proximity Read ↗

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.Semantic proximity Read ↗

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 studySemantic proximity Read ↗

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple MyelomaSemantic proximity Read ↗

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2Semantic proximity Read ↗

Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocationSemantic proximity Read ↗

Risk Stratification and Targets in Multiple Myeloma: From Genomics to the BedsideSemantic proximity Read ↗

Clinical implications of cytogenetic and molecular aberrations in multiple myelomaSemantic proximity Read ↗

Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalitiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.